The case in which the U.S. Supreme Court ruled was Bruesewitz v. Wyeth, Inc. (No. 09-152, S. Ct.). The Bruesewitz family’s daughter suffered from seizures and has permanent developmental delay, after receiving a third DTP vaccine when she was 6 months old. After losing their case in “vaccine court” (under the VICP), the Bruesewitz family sued Wyeth siting a 1998 DTP vaccine design flaw. They claimed that Wyeth had prior knowledge about the design flaw, but decided to place it on the market regardless. The Bruesewitz family filed a lawsuit against Wyeth directly with the claim that design-flaw was not protected by the VICP. Of note, 65 other children were injured by the vaccine in the same vaccine lot that their daughter received. Subsequently, the lot was pulled from the market.
It is important to note that this ruling does not make claims that vaccines do not ever cause harm. It merely offers protection so that lawsuits will not bankrupt the vaccine manufacturers causing them to pull out of the market. If a withdrawal from the vaccine market would occur, it would be considered a public health issue with devastating consequences.
For example, prior to the existence of the Haemophilus influenza (Hib) type b vaccine in 1987, approximately 20,000 U.S. children became infected with Hib meningitis, pneumonia, epiglottitis, or other invasive Hib disease. Approximately 1,000 U.S. children died per year as a result of invasive Hib disease. Per the Centers for disease Control (CDC), “the incidence of Hib disease in infants and young children has decreased by 99% to fewer than 1 case per 100,000 children under 5 years of age. In the United States, Hib disease occurs primarily in underimmunized children and among infants too young to have completed the primary immunization series.”
Of note, here are a few excellent sources regarding vaccine information: